Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Solriamfetol
Accession Number
DB14754
Type
Small Molecule
Groups
Approved
Description

Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apneaLabel. Solriamfetol was given FDA approval in 2019Label.

Structure
Thumb
Synonyms
  • (2R)-2-amino-3-phenylpropyl carbamate
  • Solriamfetol
External IDs
JZP-110 / R-228060 / SKL-N-05 / YKP-10A
Product Ingredients
IngredientUNIICASInChI Key
Solriamfetol hydrochlorideK7RO88SP7A178429-65-7KAOVAAHCFNYXNJ-SBSPUUFOSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SunosiTablet, film coated150 mg/1OralJazz Pharmaceuticals, Inc.2019-06-18Not applicableUs
SunosiTablet, film coated75 mg/1OralJazz Pharmaceuticals, Inc.2019-06-18Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
939U7C91AI
CAS number
178429-62-4
Weight
Average: 194.234
Monoisotopic: 194.105527699
Chemical Formula
C10H14N2O2
InChI Key
UCTRAOBQFUDCSR-SECBINFHSA-N
InChI
InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1
IUPAC Name
(2R)-2-amino-3-phenylpropyl carbamate
SMILES
N[C@@H](COC(N)=O)CC1=CC=CC=C1

Pharmacology

Indication

Solriamfetol is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy, but is not a treatment for the underlying airway obstruction in apnea patientsLabel2,3.

Associated Conditions
Pharmacodynamics

Solriamfetol weakly binds to dopamine and norepinephrine transporters but not serotonin transportersLabel1. Solriamfetol does not bind to dopamine, serotonin, norepinephrine, GABA, adenosine, histamine, orexin, benzodiazepines, or muscarinic and nicotinic receptorsLabel.

Solriamfetol is also associated with a mean increase of 21 beats per minute (BPM) in heart rate in patients taking 300mg (twice the maximum recommended dose) and 27 BPM in patients taking 900mg (six times the maximum recommended dose)Label. 300mg of solriamfetol does not increase the QTcF interval to a clinically relevant degreeLabel.

Mechanism of action

The specific mechanism of action is unknown but it may be through its activity as a dopamine and norepinephrine reuptake inhibitorLabel1.

TargetActionsOrganism
USodium-dependent dopamine transporterNot AvailableHumans
USodium-dependent noradrenaline transporterNot AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Oral bioavailability of solriamfetol is approximately 95%Label. Peak plasma concentration is reached in 2 hours (with a range of 1.25 to 3 hours) in fasted patientsLabel. When solriamfetol is taken with a high fat meal, the time to peak plasma concentration increases to 3 hoursLabel.

Volume of distribution

199LLabel. Other studies have found the volume of distribution to be 158.2L ± 37.3L in fasted subjects and 159.8L ± 38.9L in fed subjects3.

Protein binding

13.3% to 19.4% protein bound over a plasma concentration range of 0.059 to 10.1mcg/mLLabel.

Metabolism

Solriamfetol does not undergo significant metabolism in humans, though less than 1% of solriamfetol is metabolized to N-acetyl solriamfetolLabel1.

Route of elimination

95% of solriamfetol is recovered in urine unchanged by metabolismLabel. Less than 1% of solriamfetol is recovered as N-acetyl solriamfetolLabel1.

Half life

7.1 hoursLabel. Other studies have found the mean half life to be 6.1 ± 1.2 hours in fasted subjects and 5.9 ± 1.2 hours in fed subjects3.

Clearance

Renal clearance is 18.2L/h and total clearance is 19.5L/hLabel. Other studies have found clearance to be 18.4 ± 4.2L/h in fasted subjects and 18.8 ± 4.2L/h in fed subjects3.

Toxicity

Age, gender, and race do not significantly affect solriamfetol pharmacokinetics and no dose adjustments were made in clinical trials for patients over 65 yearsLabel.

Patients with renal failure experience increases in half life between 1.2 and 3.9 times that in healthy patientsLabel. 21% of solriamfetol was removed by hemodialysis, however time to peak concentration was not affectedLabel.

Solriamfetol is not expected to lead to adverse effects in pregnancyLabel. Maternal and fetal toxicity was seen in animal studies at ≥4 and 5 times the maximum recommended human dose and teratogenicity was seen at 19 and ≥5 times the maximum recommended human doseLabel.

Breastfed infants should be monitored for adverse reactions such as agitation, insomnia, anorexia, and reduced weight gain as solriamfetol is present in breast milkLabel. However, there is no currently available data on the effect of solriamfetol in breast milk on breast fed inantsLabel.

Safety and effectiveness of solriamfetol in pediatric patients has not been established in clinical studiesLabel.

Solriamfetol does not display different safety or effectiveness in geriatric populationsLabel.

Dosage adjustments are recommended for patients with eGFR <60mL/min/1.73m^2 and solriamfetol is not recommended for patients with an eGFR <15mL/min/1.73m^2Label.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when Solriamfetol is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Solriamfetol is combined with (S)-Warfarin.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of hypertension can be increased when Solriamfetol is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
1-benzylimidazoleThe risk or severity of hypertension can be increased when Solriamfetol is combined with 1-benzylimidazole.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of hypertension can be increased when Solriamfetol is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of hypertension can be increased when Solriamfetol is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of hypertension can be increased when Solriamfetol is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Solriamfetol is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe risk or severity of hypertension can be increased when Solriamfetol is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of hypertension can be increased when Solriamfetol is combined with 5-methoxy-N,N-dimethyltryptamine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A: Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. doi: 10.1124/jpet.118.248120. Epub 2018 Jun 11. [PubMed:29891587]
  2. Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP: Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3): A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Dec 6. doi: 10.1164/rccm.201806-1100OC. [PubMed:30521757]
  3. Zomorodi K, Kankam M, Lu Y: A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food. Clin Ther. 2019 Feb;41(2):196-204. doi: 10.1016/j.clinthera.2018.12.001. Epub 2018 Dec 28. [PubMed:30598342]
External Links
ChemSpider
8305853
Wikipedia
Solriamfetol
FDA label
Download (700 KB)
MSDS
Download (52.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentParkinson's Disease (PD) / Somnolence1
2Not Yet RecruitingSupportive CareGlioblastomas / Gliomas1
2RecruitingTreatmentNarcolepsy / Somnolence1
2RecruitingTreatmentOSAS (Obstructive Sleep Apneas Syndrome) / Somnolence1
3CompletedTreatmentNarcolepsy1
3CompletedTreatmentNarcolepsy / OSAS (Obstructive Sleep Apneas Syndrome)1
3CompletedTreatmentOSAS (Obstructive Sleep Apneas Syndrome)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral75 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8877806No2014-11-042026-06-07Us
US8440715No2013-05-142027-08-25Us
US9604917No2017-03-282026-06-07Us
US10195151No2019-02-052037-09-05Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.95 mg/mLALOGPS
logP0.62ALOGPS
logP0.86ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)15.68ChemAxon
pKa (Strongest Basic)9.08ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.34 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity53.08 m3·mol-1ChemAxon
Polarizability20.64 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A: Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. doi: 10.1124/jpet.118.248120. Epub 2018 Jun 11. [PubMed:29891587]
  2. Solriamfetol FDA Label [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A: Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. doi: 10.1124/jpet.118.248120. Epub 2018 Jun 11. [PubMed:29891587]
  2. Solriamfetol FDA Label [File]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Solriamfetol FDA Label [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Solriamfetol FDA Label [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Solriamfetol FDA Label [File]

Drug created on March 29, 2019 15:28 / Updated on November 02, 2019 04:44